TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05490147

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional tidal volume (tidal volume [ml]= ideal body weight [kg]* 10~12) group
Description: In the conventional tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 10\~12.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: low tidal (tidal volume [ml]= ideal body weight [kg] * 6~8) volume
Description: In the low tidal volume group, patients are ventilated with a tidal volume \[ml\]= ideal body weight \[kg\]\* 6\~8.
Study: NCT05531734

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NaoX Intra-Auricular Device (IAD) monitoring EEG data
Description: Intrauaricular measurement tool developed by NaoX Technology to retrieve EEG type data.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Simple psychometric tests
Description: Associated with simple and self-managed psychometric tests.
Study: NCT05099107

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol (as Salbutamol Sulfate) 2 Mg Oral Tablet
Description: taken 3 times daily for 6 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salbutamol Only Product in Oral Dose Form
Description: taken 3 times daily for 6 months
Study: NCT03707418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Heparin Sodium
Description: Intravenous Heparin titrated to Partial ThromboplastinTime (PTT) levels

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bivalirudin Injection [Angiomax]
Description: Intravenous Bivalirudin titrated to Activated Clotting Time (ACT) levels
Study: NCT06414759

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Description: Acetazolamide is a medication that belongs to the class of carbonic anhydrase inhibitors. It acts by reducing the reabsorption of sodium in the proximal tubules of the kidneys. When combined with loop diuretics, acetazolamide has the potential to enhance the effectiveness of diuretic therapy, thus aiding in the process of decongestion.~It will be given 500mg orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metolazone
Description: Metolazone is a medication with properties like thiazide diuretics, prescribed for the management of congestive heart failure and hypertension. Its mechanism of action involves blocking the transport of sodium across the epithelium of renal tubules, predominantly in the distal tubules.~It will be given 5mg orally, once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Loop Diuretics
Description: IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Loop Diuretics
Description: IV loop diuretic 2 times the outpatient oral (PO) daily dose, and oral loop diuretics will be stopped. In cases where the patient was not previously on oral diuretics, a starting dose of 40 mg of IV furosemide, IV bumetanide 1 mg or a bolus of 20 mg of IV torsemide can be utilized.
Study: NCT05525234

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Start with oral thalidomide at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
Study: NCT05037721

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gargling with green tea
Description: experimental group using 0.5% green tea gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gargling with water
Description: using water gargle, control group use clear water gargle, secondary in daily use mouthwash after breakfast and lunch after 30 minutes, 15 ml each use gargle for 30 seconds, total 7 days
Study: NCT06144788

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: SGLT 1/2 dual inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: SGLT 1/2 dual inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor
Description: SGLT 1/2 dual inhibitor
Study: NCT04137978

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ADV7103
Description: Patients receive ADV7103 twice a day at optimal dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Cohort of patients with cystinuria, matching-pair for age category to the patients of ADV7103 Cohort, will receive their own alkalinising treatment (SoC) taken at the usual dose and frequency and will follow their usual first intention treatment (hydration and diet) for a 2-year-period.
Study: NCT05525234

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Start with oral placebo at 50mg/day, increase or decrease the dose according to itching relief, the maximum dose is 100mg/day
Study: NCT00793377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen
Description: Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid
Description: Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
Study: NCT05943210

Intervention type: RADIATION
Group type: OTHER
Intervention: Short Course Radiation Therapy (scRT)
Description: Eligible patients will receive short course radiation therapy (scRT) of 25Gy over 5 days (fractions) for their localized rectal cancer. Research bloods stool and tissue will be collected at three time points: Baseline, end of radiation therapy and at surgery.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Total Mesenteric Excision (TME)
Description: Subjects are expected to undergo total mesenteric Excision(TME) even if subjects have achieved complete response by imaging.TME is a specific surgical technique used in the treatment of rectal cancer in which the bowel with the tumor is entirely removed along with surrounding fat and lymph nodes.
Study: NCT00012636

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Computer generated statements about guideline concordance of drug therapy deliver to clinicians
Study: NCT04782700

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Steroid Taper (Prednisone)
Description: The patients randomized to the steroid group will be prescribed prednisone PO or an equivalent corticosteroid at a dose of 0.5 mg/kg/day for 4 weeks ((plus BACTRIM-DS (1PO qd. 160/800mg) as prophylaxis against infection - If patient have a sulfa allergy, their physician will prescribe atovaquone 1500mg qd instead of Bactrim) and followed by a gradual taper of 0.25 mg/kg/day for 4 weeks, followed by 0.125 mg/kg qd for 4 weeks.
Study: NCT05338112

Intervention type: DIAGNOSTIC_TEST
Intervention: Tzanck smear
Description: The Tzanck smear is gently taken with a sterile scalpel from the ground of erosion or bullous lesions of pemphigus vulgaris. The sample taken is examined by staining the slide.
Study: NCT06182046

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Complete decongestive treatment program
Description: It consists of manual lymph drainage, multi-layer bandaging, skin/nail care and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Complete decongestive treatment program
Description: It consists of manual lymph drainage, multi-layer bandaging, skin/nail care and exercise treatments. The treatment will last 45 minutes/session, 5 sessions/week and 3 weeks.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance exercises
Description: These exercises will be performed in 2 sets, 5 days a week for 3 weeks. Each set will last 15 minutes. It will take 15 sessions in total. These exercises include 10 balance exercise movements performed on a bosu ball.
Study: NCT05177900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Study Tool Computer
Description: Nonconventional pulses delivered with custom-ware designed by Boston Scientific

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Study Tool Computer
Description: Nonconventional pulses delivered with custom-ware designed by Boston Scientific
Study: NCT04560621

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managed Problem Solving (MAPS)
Description: MAPS is an individual-level, problem-solving intervention delivered in person and via telephone calls to HIV clinic patients. The intervention focuses on improving medication adherence through an iterative, five-step process which consists of 1) identifying barriers to adherence, 2) brainstorming to generate potential solutions, 3) decision-making and developing a plan of action, 4) implementing the plan, and 5) evaluating and modifying the plan as necessary. In-person sessions include education related to the treatment regimen and to common medication misperceptions; problem-solving to identify daily routines, cues, cognitive aids and social supports; screening to identify barriers related to depression, substance use, toxicity management and competing demands; and review of adherence data to determine where problems have occurred and to develop solutions.
Study: NCT05659550

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Honeywell HT-900 Turbo Force Air Circulator
Description: This is a basic, portable, household fan with a single cost of CDN$21.99.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Honeywell HT-900 Turbo Force Air Circulator
Description: This is a basic, portable, household fan with a single cost of CDN$21.99.
Study: NCT06202157

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LMB
Description: A baseline blood sample (t=0) is collected from each participant prior to the intervention (LMB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DHB
Description: A baseline blood sample (t=0) is collected from each participant prior to the intervention (DHB), and subsequent blood samples are collected at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours post-intervention.
Study: NCT05260645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Back School
Description: Intervention was carried out for 8 weeks with a frequency of two sessions per week, with a total of 16 sessions lasting 45 min. Of all the sessions, 14 had a practical focus and the other two had a theoretical focus. In the practical part, strengthening and stretching exercises were performed. In the theoretical part, self-management and pain neuroscience education were performed.
Study: NCT06052540

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic supplement
Description: * Stick: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Maltodestrins~* Drops: Bifidobacterium breve M-16V, Bifidobacterium lactis HN019, Lactobacillus rhamnosus HN001 + Medium chain triglycerides, vegetable fats, emulsifier, and maltodextrin.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: * Drops: Medium Chain Triglycerides, vegetal oil, E471, and maltodextrin~* Stick: Maltodextrin.
Study: NCT05400031

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: propolis
Description: After obtaining written consent, oral identification of all participants will be performed prior to randomization. Oral diagnosis of children receiving chemotherapy will be repeated on day 0, day 5, and day 10, and the difference between the Oral Mucositis Rating Scale mean scores of the children in the groups will be examined.~Oral Mucositis Assessment: Oral Mucositis Rating Scale will be used. The oral mucosa of children will be evaluated using the World Health Organization Oral Mucositis Classification.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT05865275

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-level laser treatment
Description: a single preliminary treatment for a few seconds for each tooth using low level diode laser before of tooth bleaching could reduce risk to arise of tooth sensitivity

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: tooth bleaching procedure
Description: The gingival tissues of the teeth to be bleached were isolated from the bleaching gel using a light-cured resin dam (OpalDam Kit, Ultradent; Milan, Italy). A 38 % ready-to-use Hydrogen peroxide-containing gel (The Smile® Strong, Italy) was applied from the first premolar right to the first premolar left of both jaws for a total period of 20 minutes for a 1 single whitening session.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: tooth bleaching procedure
Description: The gingival tissues of the teeth to be bleached were isolated from the bleaching gel using a light-cured resin dam (OpalDam Kit, Ultradent; Milan, Italy). A 38 % ready-to-use Hydrogen peroxide-containing gel (The Smile® Strong, Italy) was applied from the first premolar right to the first premolar left of both jaws for a total period of 20 minutes for a 1 single whitening session.
Study: NCT05660824

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stromal Vascular Fraction infiltration
Description: Procedure to prepare SVF: In the operations room and after aseptic technic, local anesthesia is applied in the liposuction incision site with lidocaine 1% without epinephrine subcutaneously. 60 ml of tumescent solution are injected. After 15-20 minutes waiting, 15 ml of lipoaspiration per side are recollected into a double syringe. This is centrifuged for 4 minutes at 2.500 rpm and the remaining fat is separated from the other fractions. Two 1.4 mm GEMS syringes are attached together, and fat is transferred at least 30 times from one syringe to the other. Syringe content is again centrifugated for 4 minutes. The oil is discarded and approximately 1.5ml SVF fraction remains.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plattelet Rich Plasma infiltration
Description: Procedure to prepare PRP: 15 cm of peripheral blood obtained by venipuncture are centrifugated at 5000 RPM during 5 minutes. Using PRP Arthrex kit platelets poor plasma is discarded and 1-3 mm of PRP are ready to be injected
Study: NCT06016985

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: caffeine gum
Description: This study investigated the effects of chewing 3 mg/kg of caffeinated gum on basketball free throw accuracy and basketball -specific performance.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: caffeine gum
Description: This study investigated the effects of chewing 3 mg/kg of caffeinated gum on basketball free throw accuracy and basketball -specific performance.
Study: NCT05442606

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Ultrasound Therapy
Description: Using an Enraf Nonius Sonoplus 490 from the Netherlands, the patients were asked to lie supine while the therapist stood at the level of the patient's head. The patients received pulsed (duty cycle 50%) US therapy with intensities of 1 and 0.5 W/cm2 for maxillary and frontal sinus, respectively, and a collimating beam frequency of 1MHz. To deliver US to the treatment area, a small probe US applicator (0.8 cm2) with an effective radiating area (ERA) of 0.6 cm2 and a beam non-uniformity ratio (BNR) of 6:1 was used. The skin around the cheeks was used for the maxillary sinus and the forehead for the frontal sinus. Between the applicator and the skin, ultrasound transmission gel was employed, and a full contact technique in slow circular motion was used for 5 minutes over the maxillary sinuses and 4 minutes over the frontal sinuses on each pair of sinuses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Drainage Techniques
Description: Manual Drainage Techniques for the frontal and maxillary sinuses

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self Sinus Massage Technique
Description: Patients will also encouraged to self-massage their frontal and maxillary sinuses while resting supine
Study: NCT05530200

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy
Description: 24Gy/8Gy/3f

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-L1 inhibitor
Description: q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GM-CSF
Description: 200μg, D1-D7

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL-2
Description: at a dose of 2 million IU, D8-D14
Study: NCT05679817

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dose-graded aerobic exercises
Description: The D-GAE group received a 12-week aerobic training, three times in addition to the traditional physical rehabilitation. The D-GAE program commenced with a training intensity corresponding to 50% of the maximum age-predicted heart rate for 25 minutes in the first two weeks, which progressed on a two-week basis, and ended up with a training intensity corresponding to 75% of the maximum age-predicted heart rate for 50 minutes in the last two weeks. The D-GAE program included a warm-up for 5 minutes and a cool-down for 5 minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional physical rehabilitation
Description: The control group received the traditional physical rehabilitation only, 45 minutes per session, three times a week for 12 consecutive weeks. The program consisted of flexibility exercises, strengthening exercises, balance training, and general conditioning exercises.
Study: NCT05259384

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic pancreaticoduodenectomy
Description: The Intervention of MIPD-ROB group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic pancreaticoduodenectomy
Description: The Intervention of MIPD-LAP group

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Distal Pancreatectomy
Description: The Intervention of MIDP-ROB group

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Distal Pancreatectomy
Description: The Intervention of MIDP-LAP group
Study: NCT05171634

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DiscoveryTM
Description: Colonoscopy assisted by an artificial intelligence system (DiscoveryTM).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iSCAN
Description: Virtual colonoscopy assisted by iSCAN
Study: NCT05073354

Intervention type: DEVICE
Intervention: Full SWOT Model
Description: Bundle of care that includes devices such as X Series monitor/defibrillator, AutoPusle automated compression device, Z Vent ventilator, and IPR therapies as well as bedside monitoring and diagnostics and training on a standardized care process.
Study: NCT05240469

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Automated sperm selection software
Description: The software measures both morphology and motility similar to an embryologist but provides a more accurate and consistent measure of sperm characteristics. Embryologists use their experience to qualitatively judge if an individual sperm is suitable for injection based on morphology and motility. Similarly, the software follows a two-step process: firstly, a computer vision algorithm measures characteristics of all sperm in a given field, including motility and morphology; secondly, the software algorithm then uses a set of quantitative criteria to categorize and identify the most developmentally competent sperm with normal characteristics. All the characteristics that the software calculate are defined by the WHO guidelines, and the software does not propose or define new parameters.
Study: NCT05233098

Intervention type: DEVICE
Intervention: Technetium-99m macroaggregated albumin (Tc-99m MAA)
Description: Patients who are being evaluated for TheraSphere administration.
Study: NCT06255912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004 + MIL-97
Description: Dose group 1：MIL97:0.2mg/kg,Day1,Q3W,LTC004:90ug/kg,Day3,Q3W Dose group 2:MIL97:0.2mg/kg,Day1,Q3W,LTC004:180ug/kg,Day3,Q3W Dose group -1:MIL97:0.2mg/kg,Day1,Q3W,LTC004:45ug/kg,Day3,Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTC004 + MIL-97+chemotherapy
Description: LTC004 + MIL-97+chemotherapy
Study: NCT06080906

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IRV on a 0- and 28-day schedule
Description: Inactivated Rotavirus vaccine (Vero Cells) of 320EU/0.5ml on Day 0, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IRV on a 0-, 28- and 56-day schedule
Description: Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on Day 0, 28, 56

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on Day 0, 28
Description: Two doses of placebo at the vaccination schedule of Day 0, 28
Study: NCT04816708

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LIFT Mindfulness
Description: Mindfulness is a type of mind-body therapy that promotes a practice of non-judgmental awareness that can alleviate distress by uncoupling emotional reactions and habitual behavior from unpleasant symptoms, thoughts, and emotions. LIFT is a mobile mindfulness app which can assess levels of emotional distress via survey, and subsequently offer mindfulness content that has previously been used in ICU patients, where it was shown to reduce symptoms of depression, anxiety, and PTSD.
Study: NCT05906901

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Cranial listening technique
Description: 5 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suboccipital muscles inhibition technique
Description: 6 minutes
Study: NCT06074445

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05762081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Disposable Wipes for wiping baths
Description: A disposable wipe bath is a type of bath that is applied to bed-bound or unconscious patients and weak individuals by wiping the entire body.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Traditional bed bath
Description: Traditional bed bathing is a type of bathing applied to bed-bound or unconscious patients and weak individuals by wiping the entire body with soap and water.
Study: NCT06080906

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on Day 0, 28, 56
Description: Three doses of placebo at the vaccination schedule of Day 0, 28, 56